Vimarsana
Biggest News Aggregation in the World

Page 21 - Manufacturing Program News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Manufacturing Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Manufacturing Program Today - Breaking & Trending Today

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List - Vimarsana News

China's First and Only Approved Third-Generation BCR-ABL Inhibitor Olverembatinib Included into the 2022 National Reimbursement Drug List

/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...

India's Incentive Schemes for the Electronics and IT Sectors - Vimarsana News

India's Incentive Schemes for the Electronics and IT Sectors

Through these initiatives, India hopes to boost domestic electronics manufacturing and exports, including semiconductors, and move up the electronics value chain.

Union Budget for 2023–24: Calculative actions to strengthen domestic sources of growth are essential - Vimarsana News

Union Budget for 2023–24: Calculative actions to strengthen domestic sources of growth are essential

The consumer durables and electronics industry will contribute to strengthening the Indian economy. It is expected that the Union Budget FY2024 to include reforms that stimulate consumption and improve consumer demand.

FDA Roundup: November 29, 2022 - Vimarsana News

FDA Roundup: November 29, 2022

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued two...

FDA Roundup: November 29, 2022 - Vimarsana News

FDA Roundup: November 29, 2022

/PRNewswire/ -- Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA issued two...